Thrombotic Thrombocytopenic Purpura and High-Dose Immunoglobulin Treatment
Authors: P. VIERO
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 February 1986Thrombotic Thrombocytopenic Purpura and High-Dose Immunoglobulin TreatmentP. VIERO, S. CORTELAZZO, M. BUELLI, B. COMOTTI, B. MlNETTI, R. BASSAN, T. BARBUIP. VIEROSearch for more papers by this author, S. CORTELAZZOSearch for more papers by this author, M. BUELLISearch for more papers by this author, B. COMOTTISearch for more papers by this author, B. MlNETTISearch for more papers by this author, R. BASSANSearch for more papers by this author, T. BARBUISearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-104-2-282_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Thrombotic thrombocytopenic purpura, a syndrome with a grave prognosis, is characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, and fever due to microthrombi formation in the capillaries of almost any tissue. Plasma transfusion and exchange have become the most used therapeutic methods.The reason for the beneficial effects of this therapeutic procedure is unclear. Normal plasma can supply a factor stimulating release of prostacyclin (1) and factor VIII:von Willebrand factor depolymerase (2). Plasma of some patients with thrombotic thrombocytopenic purpura would contain a platelet-aggregating factor resulting from infectious and noninfectious agents (3, 4), whereas normal plasma would...References1. REMUZZIIMBERTIDE GAETANO GLG Prostacyclin deficiency in thrombotic microangiopathy. Lancet. 1981;2:1422-3. CrossrefMedlineGoogle Scholar2. MOAKERUDYTROLL JCJ. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432-5. CrossrefMedlineGoogle Scholar3. LIANHARKNESSBYRNESWALLECHNUMER EDJHR. Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood. 1979;53:333-8. CrossrefMedlineGoogle Scholar4. KELTONMOORESANTOSSHERIDAN JJAD. Detection of a platelet agglutinating-factor in thrombotic thrombocytopenic purpura. Ann Intern Med. 1984;101:589-93. LinkGoogle Scholar5. LIANMUISIDDIQUICHINCHIN EPFAL. Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G. J Clin Invest. 1984;73:548-55. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Ospedali Riuniti di Bergamo 24100 Bergamo Italy PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBone Marrow Transplant Associated Thrombotic MicroangiopathyCurrent Clinical Practice: Current Management of Thrombotic Thrombocytopenic Purpura14 Thrombotic thrombocytopenic purpura: diagnosis, pathogenesis and modern therapyThrombotic MicroangiopathyTreatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorptionThe pathophysiology and management of thrombotic thrombocytopenic purpuraHigh-dose human immunoglobulins in thrombotic thrombocytopenic purpuraHaemolytic—Uraemic Syndrome and Thrombotic Thrombocytopenic PurpuraIntravenous immunoglobulin treatment in cytopenic haematological disordersThe changing course of thrombotic thrombocytopenic purpura and modern therapyThrombotic Thrombocytopenic Purpura Resistant to Plasma-exchange: Salvage Treatment with High-dose IgG or VincristineIneffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpuraCase Report: High-Dose Intravenous Immunoglobulin As Therapy for Thrombotic Thrombocytopenic PurpuraInefficacy of intravenous immunoglobulin in patients with low-risk thrombotic thrombocytopenic purpura/hemolytic-uremic syndromeDiagnose und Differentialdiagnose hämolytischer AnämienThrombotic thrombocytopenic purpura: Clinical results of a French controlled trialThrombotic microangiopathiesImproved Survival in Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic SyndromeShould Intravenous Immunoglobulin G Be First-Line Treatment for Acute Thrombotic Thrombocytopenic Purpura?: Case Report and Review of the LiteratureBias due to publication of positive results with treatments for thrombotic thrombocytopenic purpuraEfficacy of the high molecular weight fraction of plasma for the maintenance of pregnancy associated with thrombotic thrombocytopenic purpuraSplenectomy for chronic thrombotic thrombocytopenic purpuraThrombotic Thrombocytopenic Purpura and Related DisordersEffects of Repeated Doses of Intravenous Immunoglobulin in Myasthenia GravisIntravenous Immunoglobulins as Therapeutic AgentsE. RICHARD STIEHM, M.D., ELLYN ASHIDA, M.D., KWANG SIK KIM, M.D., DREW J. WINSTON, M.D., ALBERT HAAS, M.D., ROBERT P. GALE, M.D., Ph.D.High incidence of relapses in thrombotic thrombocytopenic purpuraHUS and TTP: Variable expression of a single entity 1 February 1986Volume 104, Issue 2Page: 282-282KeywordsBlood plasmaCapillariesFeversHemolytic anemiaProstacyclinThrombotic thrombocytopenic purpura ePublished: 1 December 2008 Issue Published: 1 February 1986 PDF downloadLoading ...